Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Serious reactions are rare
Net-beneficial preferred terms uric acid lowered -0.69/-0.92/-0.95 mg/dL (72.7% mediated by weight loss): Sattar Annals of the Rheumatic Diseases 2026
No obvious weight loss yet- but again its only been 3 weeks so I am sure this will change over time
Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
A patient with diffuse or multi-site damage, post-surgical healing needs across multiple tissue types, or chronic systemic inflammation gets the full combination because the systemic reach of TB-500 covers what BPC-157 cannot address on its own
